RAC-3-N-BUTYLPHTHALIDE

Summary

Rac-3-N-Butylphthalide (CHEMBL248594) is a phase-3 clinical-stage small molecule; indicated across 4 conditions including vascular dementia and stroke disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 4 conditions
• Clinical trials: 21
• Chemistry: 190.24 Da · C12H14O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL248594
Name	RAC-3-N-BUTYLPHTHALIDE
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	61361
Molecular formula	C12H14O2
Molecular weight	190.24
InChIKey	HJXMNVQARNZTEE-UHFFFAOYSA-N

SMILES: CCCCC1C2=CC=CC=C2C(=O)O1

IUPAC name: 3-butyl-3H-2-benzofuran-1-one

Also known as: n-butylphthalide, butylphthalide, BUTYLPHTHALIDE, Butylphthalide, n-Butylphthalide

Patent coverage: 1,321 distinct patent families (2,547 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Glutamate NMDA receptor.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P35439	7.83	Ki	14.8	nM	CHEMBL_ACT_24790906

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
vascular dementia	3	MONDO:0004648	EFO:0004718
stroke disorder	1	MONDO:0005098	EFO:0000712

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 21.

Phase distribution

Phase	Trials
PHASE4	8
PHASE3	6
Not specified	4
PHASE2/PHASE3	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06353334	PHASE4	RECRUITING	Butylphthalide’s Safety and Efficacy for Improving Neurological Function Prognosis in Patients With Cardiac Arrest (BNCA Trial)
NCT06508671	PHASE4	NOT_YET_RECRUITING	Effects of DL-3-n-butylphthalide on Chemotherapy-Induced Cognitive Impairment
NCT06572085	PHASE4	RECRUITING	Neuroprotective Effect of Butylphthalide for Cardiac Arrest Patients
NCT07193277	PHASE4	RECRUITING	Butylphthalide for Cognitive Impairment in Elderly Patients With Focal Epilepsy
NCT07528456	PHASE4	NOT_YET_RECRUITING	Butylphthalide for Brain Edema After Endovascular Treatment
NCT00724724	PHASE4	UNKNOWN	The Effectiveness and Safety of Butylphthalide Soft Capsules in Secondary Prevention of Ischemic Stroke Trial
NCT04091412	PHASE4	UNKNOWN	Study of Collateral Circulation in Patients With Symptomatic Intracranial Anterior Circulation Occlusion
NCT05068349	PHASE4	UNKNOWN	For Patients With Ischemic Stroke, Clinically Study the Effectiveness and Safety of Butylphthalide.
NCT06704685	PHASE3	NOT_YET_RECRUITING	A Randomized Controlled Trial on the Efficacy and Safety of Butylphthalide in Reducing Myocardial Infarction Size and Improving Outcomes in STEMI Patients After Primary PCI
NCT07230587	PHASE3	NOT_YET_RECRUITING	Butylphthalide for Long-term Efficacy in Minor Stroke Study
NCT07252544	PHASE3	NOT_YET_RECRUITING	Isosorbide Mononitrate and Butylphthalide to Reduce the Risk of Disability in Patients With Acute Lacunar Stroke (IMPACT)
NCT07518810	PHASE2/PHASE3	NOT_YET_RECRUITING	Efficacy and Safety of Butylphthalide in the Treatment of Multiple System Atrophy
NCT01405248	PHASE3	COMPLETED	Butylphthalide for Preventing Restenosis After Intracranial and Extracranial Artery Stenting
NCT02993367	PHASE2/PHASE3	UNKNOWN	The Efficacy of Butylphthalide Soft Capsules in Patents With VCIND
NCT03539445	PHASE3	COMPLETED	Efficacy and Safety of Butylphthalide for Acute Ischemic Stroke Patients Receiving Intravenous Thrombolysis or Endovascular Treatment
NCT04205578	PHASE3	UNKNOWN	NBP in Patients With Moyamoya Disease of High Risk for Ischemic Cerebrovascular Events
NCT02149875	PHASE1/PHASE2	COMPLETED	Dl-3-n-butylphthalide and Cerebrolysin Treatment in Acute Ischemic Stroke
NCT06331494	Not specified	NOT_YET_RECRUITING	Efficacy of Butylphthalide on Symptomatic Atherosclerotic Stenosis in Middle Cerebral Artery
NCT02711683	Not specified	COMPLETED	DL-3-n-butylphthalide Treatment in Patients With Mild to Moderate Alzheimer’s Disease Already Receiving Donepezil
NCT04078204	Not specified	UNKNOWN	A Clinical Study on the Treatment of Cerebral Small Vascular Disease
NCT05086874	Not specified	COMPLETED	Using Real-world Evidence to Analyze the Clinical Effects and Adverse Events of Butylphthalide in Stroke Patients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).